Sirnaomics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Alan Patrick Lu
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 47.4% |
| CEO tenure | 3.6yrs |
| CEO ownership | 10.7% |
| Management average tenure | 1.3yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$1m | US$515k | -US$79m |
| Sep 30 2023 | n/a | n/a | -US$82m |
| Jun 30 2023 | n/a | n/a | -US$84m |
| Mar 31 2023 | n/a | n/a | -US$86m |
| Dec 31 2022 | US$602k | US$520k | -US$88m |
| Sep 30 2022 | n/a | n/a | -US$230m |
| Jun 30 2022 | n/a | n/a | -US$223m |
| Mar 31 2022 | n/a | n/a | -US$218m |
| Dec 31 2021 | US$4m | US$379k | -US$213m |
| Sep 30 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$370k | US$276k | -US$44m |
| Dec 31 2019 | US$379k | US$277k | -US$16m |
Compensation vs Market: Alan Patrick's total compensation ($USD1.09M) is above average for companies of similar size in the Hong Kong market ($USD232.74K).
Compensation vs Earnings: Alan Patrick's compensation has increased whilst the company is unprofitable.
CEO
Alan Patrick Lu (67 yo)
3.6yrs
Tenure
US$1,086,000
Compensation
Dr. Yang Lu, also known as Alan Patrick, PhD., is the founder, serves as Chairman of the Board, President & Chief Executive Officer at Sirnaomics Ltd. and has been its Director since October 15, 2020. He i...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| China Chief Scientific Officer | no data | US$1.09m | 10.7% $ 66.1m | |
| Head of Drug Discovery & Collaboration and Executive Director | 1.3yrs | US$469.00k | 0.12% $ 743.0k | |
| Chief Strategy Officer & Executive Director | 1.8yrs | US$885.00k | 2.03% $ 12.5m | |
| Group Chief Financial Officer | 5.6yrs | no data | no data | |
| Vice President of Human Resources | 1.3yrs | no data | no data | |
| Chief Production Officer | no data | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Company Secretary | no data | no data | no data |
1.3yrs
Average Tenure
60yo
Average Age
Experienced Management: 2257's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| China Chief Scientific Officer | 3.6yrs | US$1.09m | 10.7% $ 66.1m | |
| Head of Drug Discovery & Collaboration and Executive Director | 2.8yrs | US$469.00k | 0.12% $ 743.0k | |
| Chief Strategy Officer & Executive Director | 3.3yrs | US$885.00k | 2.03% $ 12.5m | |
| Independent Non Executive Director | 2.4yrs | US$69.00k | no data | |
| Independent Non Executive Director | 2.4yrs | US$46.00k | no data | |
| Independent Non Executive Director | 2.4yrs | US$46.00k | no data | |
| Independent Non-Executive Director | 2.4yrs | US$69.00k | no data | |
| Non Executive Director | 2.8yrs | US$15.00k | no data | |
| Non Executive Director | 3.3yrs | US$15.00k | 0.87% $ 5.4m |
2.8yrs
Average Tenure
60yo
Average Age
Experienced Board: 2257's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.